1
|
Yamada Y, Takashima H, Walmsley DL, Ushiyama F, Matsuda Y, Kanazawa H, Yamaguchi-Sasaki T, Tanaka-Yamamoto N, Yamagishi J, Kurimoto-Tsuruta R, Ogata Y, Ohtake N, Angove H, Baker L, Harris R, Macias A, Robertson A, Surgenor A, Watanabe H, Nakano K, Mima M, Iwamoto K, Okada A, Takata I, Hitaka K, Tanaka A, Fujita K, Sugiyama H, Hubbard RE. Fragment-Based Discovery of Novel Non-Hydroxamate LpxC Inhibitors with Antibacterial Activity. J Med Chem 2020; 63:14805-14820. [DOI: 10.1021/acs.jmedchem.0c01215] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- Yousuke Yamada
- Taisho Pharmaceutical Co., Ltd., Saitama 331-9530, Japan
| | | | | | | | - Yohei Matsuda
- Taisho Pharmaceutical Co., Ltd., Saitama 331-9530, Japan
| | | | | | | | | | | | - Yuya Ogata
- Taisho Pharmaceutical Co., Ltd., Saitama 331-9530, Japan
| | | | - Hayley Angove
- Vernalis (R&D) Ltd., Granta Park, Cambridge CB21 6GB, U.K
| | - Lisa Baker
- Vernalis (R&D) Ltd., Granta Park, Cambridge CB21 6GB, U.K
| | - Richard Harris
- Vernalis (R&D) Ltd., Granta Park, Cambridge CB21 6GB, U.K
| | - Alba Macias
- Vernalis (R&D) Ltd., Granta Park, Cambridge CB21 6GB, U.K
| | - Alan Robertson
- Vernalis (R&D) Ltd., Granta Park, Cambridge CB21 6GB, U.K
| | - Allan Surgenor
- Vernalis (R&D) Ltd., Granta Park, Cambridge CB21 6GB, U.K
| | | | | | - Masashi Mima
- Taisho Pharmaceutical Co., Ltd., Saitama 331-9530, Japan
| | | | - Atsushi Okada
- Taisho Pharmaceutical Co., Ltd., Saitama 331-9530, Japan
| | - Iichiro Takata
- Taisho Pharmaceutical Co., Ltd., Saitama 331-9530, Japan
| | - Kosuke Hitaka
- Taisho Pharmaceutical Co., Ltd., Saitama 331-9530, Japan
| | - Akihiro Tanaka
- Taisho Pharmaceutical Co., Ltd., Saitama 331-9530, Japan
| | - Kiyoko Fujita
- Taisho Pharmaceutical Co., Ltd., Saitama 331-9530, Japan
| | | | | |
Collapse
|
2
|
Maragno AL, Mistry P, Kotschy A, Szlavik Z, Murray J, Davidson J, Toumelin-Braizat GL, Chanrion M, Bruno A, Claperon A, Maacke H, Morris E, Wang Y, Derreal A, Csekei M, Paczal A, Szabo Z, Sipos S, Proszenyak A, Balint B, Surgenor A, Dokurno P, Matassova N, Chen I, Lysiak-Auvity G, Girard AM, Grave F, Colland F, Halilovic E, Geneste O. Abstract 4482: S64315 (MIK665) is a potent and selective Mcl1 inhibitor with strong antitumor activity across a diverse range of hematologic tumor models. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-4482] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Mcl-1 is highly expressed in a variety of human cancers (including those of hematopoietic and lymphoid origin) and is exploited by cancer cells to evade cell death and to develop resistance to diverse chemotherapeutic agents. We disclose, for the first time, the structure of S64315 (also named MIK665) a highly potent and selective inhibitor of Mcl-1 with improved potency over its predecessor S63845 (Kotschy et al, Nature, 2016). S64315/MIK665 is currently in phase 1 in AML (Acute Myeloid Leukemia) and MDS (Myelodysplastic Syndrome) (EudraCT 2016-003768-38, NCT 02979366) and in MM (Multiple Myeloma) and lymphoma (NCT02992483). A fragment-based, structure-guided drug discovery effort led to the identification of S64315/MIK665 that binds to human Mcl-1 with a sub-nanomolar affinity (Ki 0.048 nM) and selectively over other anti-apoptotic Bcl-2 family members. It has similar affinity for human, rat, dog and monkey Mcl-1 but about a ten-fold lower affinity for mouse Mcl-1. S64315/MIK665 causes dose-dependent activation of the intrinsic apoptosis pathway in a Bax/Bak-dependent manner, as measured by increased caspase activity and cleaved PARP. S64315/MIK665 shows strong cell killing activity in a diverse panel of human hematological tumor cell lines, including AML, lymphoma and MM. The activity profile of S64315/MIK665 is distinct from that of venetoclax, a selective Bcl2 inhibitor. In vivo, S64315 as single agent demonstrated potent and dose-dependent apoptotic and antitumor response after intravenous administration in several human hematological tumor models grafted in immuno-compromised mice and rats. Complete regression of established tumors, at well tolerated doses, was achieved using different intravenous dosing regimens in rats as well as in mice. Finally, dual BH3-mimetic targeting approach combining S64315/MIK665 with BCL2 inhibitors showed strong and durable antitumor responses in several hematological tumor models both in vitro and in vivo.
Citation Format: Ana Leticia Maragno, Prakash Mistry, András Kotschy, Zoltán Szlavik, James Murray, James Davidson, Gaëtane Le Toumelin-Braizat, Maïa Chanrion, Alain Bruno, Audrey Claperon, Heiko Maacke, Erick Morris, Youzhen Wang, Alix Derreal, Márton Csekei, Attila Paczal, Zoltán Szabo, Szabolcs Sipos, Agnes Proszenyak, Balázs Balint, Allan Surgenor, Pawel Dokurno, Natalia Matassova, Ijen Chen, Gaëlle Lysiak-Auvity, Anne-Marie Girard, Fabienne Grave, Frédéric Colland, Ensar Halilovic, Olivier Geneste. S64315 (MIK665) is a potent and selective Mcl1 inhibitor with strong antitumor activity across a diverse range of hematologic tumor models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4482.
Collapse
Affiliation(s)
| | - Prakash Mistry
- 2Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - András Kotschy
- 3Servier Research Institute of Medicinal Chemistry, Budapest, Hungary
| | - Zoltán Szlavik
- 3Servier Research Institute of Medicinal Chemistry, Budapest, Hungary
| | | | | | | | - Maïa Chanrion
- 1Institut de Recherche Servier, Croissy sur Seine, France
| | - Alain Bruno
- 5Institut de Recherches Internationales Servier, Suresnes, France
| | | | - Heiko Maacke
- 2Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - Erick Morris
- 6Novartis Institutes for BioMedical Research, Cambridge, MA
| | - Youzhen Wang
- 6Novartis Institutes for BioMedical Research, Cambridge, MA
| | - Alix Derreal
- 5Institut de Recherches Internationales Servier, Suresnes, France
| | - Márton Csekei
- 3Servier Research Institute of Medicinal Chemistry, Budapest, Hungary
| | - Attila Paczal
- 3Servier Research Institute of Medicinal Chemistry, Budapest, Hungary
| | - Zoltán Szabo
- 3Servier Research Institute of Medicinal Chemistry, Budapest, Hungary
| | - Szabolcs Sipos
- 3Servier Research Institute of Medicinal Chemistry, Budapest, Hungary
| | - Agnes Proszenyak
- 3Servier Research Institute of Medicinal Chemistry, Budapest, Hungary
| | - Balázs Balint
- 3Servier Research Institute of Medicinal Chemistry, Budapest, Hungary
| | | | | | | | - Ijen Chen
- 4Vernalis (R&D) Ltd, Cambridge, United Kingdom
| | | | | | - Fabienne Grave
- 1Institut de Recherche Servier, Croissy sur Seine, France
| | | | | | | |
Collapse
|
3
|
Szlávik Z, Ondi L, Csékei M, Paczal A, Szabó ZB, Radics G, Murray J, Davidson J, Chen I, Davis B, Hubbard RE, Pedder C, Dokurno P, Surgenor A, Smith J, Robertson A, LeToumelin-Braizat G, Cauquil N, Zarka M, Demarles D, Perron-Sierra F, Claperon A, Colland F, Geneste O, Kotschy A. Structure-Guided Discovery of a Selective Mcl-1 Inhibitor with Cellular Activity. J Med Chem 2019; 62:6913-6924. [DOI: 10.1021/acs.jmedchem.9b00134] [Citation(s) in RCA: 29] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- Zoltan Szlávik
- Servier Research Institute of Medicinal Chemistry, Záhony u. 7., H-1031 Budapest, Hungary
| | - Levente Ondi
- Servier Research Institute of Medicinal Chemistry, Záhony u. 7., H-1031 Budapest, Hungary
| | - Márton Csékei
- Servier Research Institute of Medicinal Chemistry, Záhony u. 7., H-1031 Budapest, Hungary
| | - Attila Paczal
- Servier Research Institute of Medicinal Chemistry, Záhony u. 7., H-1031 Budapest, Hungary
| | - Zoltán B. Szabó
- Servier Research Institute of Medicinal Chemistry, Záhony u. 7., H-1031 Budapest, Hungary
| | - Gábor Radics
- Servier Research Institute of Medicinal Chemistry, Záhony u. 7., H-1031 Budapest, Hungary
| | - James Murray
- Vernalis (R&D) Ltd., Granta Park, Cambridge CB21 6GB, U.K
| | - James Davidson
- Vernalis (R&D) Ltd., Granta Park, Cambridge CB21 6GB, U.K
| | - Ijen Chen
- Vernalis (R&D) Ltd., Granta Park, Cambridge CB21 6GB, U.K
| | - Ben Davis
- Vernalis (R&D) Ltd., Granta Park, Cambridge CB21 6GB, U.K
| | | | | | - Pawel Dokurno
- Vernalis (R&D) Ltd., Granta Park, Cambridge CB21 6GB, U.K
| | - Allan Surgenor
- Vernalis (R&D) Ltd., Granta Park, Cambridge CB21 6GB, U.K
| | - Julia Smith
- Vernalis (R&D) Ltd., Granta Park, Cambridge CB21 6GB, U.K
| | - Alan Robertson
- Vernalis (R&D) Ltd., Granta Park, Cambridge CB21 6GB, U.K
| | | | - Nicolas Cauquil
- Institute de Recherche Servier, 125 Chemin de Ronde, 78290 Croissy-sur-Seine, France
| | - Marion Zarka
- Institute de Recherche Servier, 125 Chemin de Ronde, 78290 Croissy-sur-Seine, France
| | - Didier Demarles
- Technologie Servier, 27 Rue Eugène Vignat, 45000 Orleans, France
| | | | - Audrey Claperon
- Institute de Recherche Servier, 125 Chemin de Ronde, 78290 Croissy-sur-Seine, France
| | - Frederic Colland
- Institute de Recherche Servier, 125 Chemin de Ronde, 78290 Croissy-sur-Seine, France
| | - Olivier Geneste
- Institute de Recherche Servier, 125 Chemin de Ronde, 78290 Croissy-sur-Seine, France
| | - András Kotschy
- Servier Research Institute of Medicinal Chemistry, Záhony u. 7., H-1031 Budapest, Hungary
| |
Collapse
|
4
|
Brough PA, Baker L, Bedford S, Brown K, Chavda S, Chell V, D'Alessandro J, Davies NGM, Davis B, Le Strat L, Macias AT, Maddox D, Mahon PC, Massey AJ, Matassova N, McKenna S, Meissner JWG, Moore JD, Murray JB, Northfield CJ, Parry C, Parsons R, Roughley SD, Shaw T, Simmonite H, Stokes S, Surgenor A, Stefaniak E, Robertson A, Wang Y, Webb P, Whitehead N, Wood M. Application of Off-Rate Screening in the Identification of Novel Pan-Isoform Inhibitors of Pyruvate Dehydrogenase Kinase. J Med Chem 2017; 60:2271-2286. [PMID: 28199108 DOI: 10.1021/acs.jmedchem.6b01478] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Libraries of nonpurified resorcinol amide derivatives were screened by surface plasmon resonance (SPR) to determine the binding dissociation constant (off-rate, kd) for compounds binding to the pyruvate dehydrogenase kinase (PDHK) enzyme. Parallel off-rate measurements against HSP90 and application of structure-based drug design enabled rapid hit to lead progression in a program to identify pan-isoform ATP-competitive inhibitors of PDHK. Lead optimization identified selective sub-100-nM inhibitors of the enzyme which significantly reduced phosphorylation of the E1α subunit in the PC3 cancer cell line in vitro.
Collapse
Affiliation(s)
- Paul A Brough
- Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge CB21 6GB, U.K
| | - Lisa Baker
- Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge CB21 6GB, U.K
| | - Simon Bedford
- Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge CB21 6GB, U.K
| | - Kirsten Brown
- Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge CB21 6GB, U.K
| | - Seema Chavda
- Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge CB21 6GB, U.K
| | - Victoria Chell
- Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge CB21 6GB, U.K
| | | | | | - Ben Davis
- Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge CB21 6GB, U.K
| | - Loic Le Strat
- Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge CB21 6GB, U.K
| | - Alba T Macias
- Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge CB21 6GB, U.K
| | - Daniel Maddox
- Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge CB21 6GB, U.K
| | - Patrick C Mahon
- Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge CB21 6GB, U.K
| | - Andrew J Massey
- Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge CB21 6GB, U.K
| | - Natalia Matassova
- Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge CB21 6GB, U.K
| | - Sean McKenna
- Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge CB21 6GB, U.K
| | | | - Jonathan D Moore
- Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge CB21 6GB, U.K
| | - James B Murray
- Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge CB21 6GB, U.K
| | | | - Charles Parry
- Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge CB21 6GB, U.K
| | - Rachel Parsons
- Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge CB21 6GB, U.K
| | - Stephen D Roughley
- Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge CB21 6GB, U.K
| | - Terry Shaw
- Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge CB21 6GB, U.K
| | - Heather Simmonite
- Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge CB21 6GB, U.K
| | - Stephen Stokes
- Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge CB21 6GB, U.K
| | - Allan Surgenor
- Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge CB21 6GB, U.K
| | - Emma Stefaniak
- Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge CB21 6GB, U.K
| | - Alan Robertson
- Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge CB21 6GB, U.K
| | - Yikang Wang
- Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge CB21 6GB, U.K
| | - Paul Webb
- Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge CB21 6GB, U.K
| | - Neil Whitehead
- Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge CB21 6GB, U.K
| | - Mike Wood
- Vernalis (R&D) Ltd. , Granta Park, Great Abington, Cambridge CB21 6GB, U.K
| |
Collapse
|
5
|
Brough PA, Barril X, Borgognoni J, Chene P, Davies NGM, Davis B, Drysdale MJ, Dymock B, Eccles SA, Garcia-Echeverria C, Fromont C, Hayes A, Hubbard RE, Jordan AM, Jensen MR, Massey A, Merrett A, Padfield A, Parsons R, Radimerski T, Raynaud FI, Robertson A, Roughley SD, Schoepfer J, Simmonite H, Sharp SY, Surgenor A, Valenti M, Walls S, Webb P, Wood M, Workman P, Wright L. Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. J Med Chem 2009; 52:4794-809. [PMID: 19610616 DOI: 10.1021/jm900357y] [Citation(s) in RCA: 129] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Inhibitors of the Hsp90 molecular chaperone are showing considerable promise as potential molecular therapeutic agents for the treatment of cancer. Here we describe novel 2-aminothieno[2,3-d]pyrimidine ATP competitive Hsp90 inhibitors, which were designed by combining structural elements of distinct low affinity hits generated from fragment-based and in silico screening exercises in concert with structural information from X-ray protein crystallography. Examples from this series have high affinity (IC50 = 50-100 nM) for Hsp90 as measured in a fluorescence polarization (FP) competitive binding assay and are active in human cancer cell lines where they inhibit cell proliferation and exhibit a characteristic profile of depletion of oncogenic proteins and concomitant elevation of Hsp72. Several examples (34a, 34d and 34i) caused tumor growth regression at well tolerated doses when administered orally in a human BT474 human breast cancer xenograft model.
Collapse
Affiliation(s)
- Paul A Brough
- Vernalis Ltd., Granta Park, Great Abington, Cambridge CB21 6GB, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Brough PA, Aherne W, Barril X, Borgognoni J, Boxall K, Cansfield JE, Cheung KMJ, Collins I, Davies NGM, Drysdale MJ, Dymock B, Eccles SA, Finch H, Fink A, Hayes A, Howes R, Hubbard RE, James K, Jordan AM, Lockie A, Martins V, Massey A, Matthews TP, McDonald E, Northfield CJ, Pearl LH, Prodromou C, Ray S, Raynaud FI, Roughley SD, Sharp SY, Surgenor A, Walmsley DL, Webb P, Wood M, Workman P, Wright L. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem 2007; 51:196-218. [PMID: 18020435 DOI: 10.1021/jm701018h] [Citation(s) in RCA: 332] [Impact Index Per Article: 19.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Inhibitors of the Hsp90 molecular chaperone are showing considerable promise as potential chemotherapeutic agents for cancer. Here, we describe the structure-based design, synthesis, structure-activity relationships and pharmacokinetics of potent small-molecule inhibitors of Hsp90 based on the 4,5-diarylisoxazole scaffold. Analogues from this series have high affinity for Hsp90, as measured in a fluorescence polarization (FP) competitive binding assay, and are active in cancer cell lines where they inhibit proliferation and exhibit a characteristic profile of depletion of oncogenic proteins and concomitant elevation of Hsp72. Compound 40f (VER-52296/NVP-AUY922) is potent in the Hsp90 FP binding assay (IC50 = 21 nM) and inhibits proliferation of various human cancer cell lines in vitro, with GI50 averaging 9 nM. Compound 40f is retained in tumors in vivo when administered i.p., as evaluated by cassette dosing in tumor-bearing mice. In a human colon cancer xenograft model, 40f inhibits tumor growth by approximately 50%.
Collapse
Affiliation(s)
- Paul A Brough
- Vernalis Ltd., Granta Park, Great Abington, Cambridge CB21 6GB, U.K. p.brough@ vernalis.com
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Sharp SY, Prodromou C, Boxall K, Powers MV, Holmes JL, Box G, Matthews TP, Cheung KMJ, Kalusa A, James K, Hayes A, Hardcastle A, Dymock B, Brough PA, Barril X, Cansfield JE, Wright L, Surgenor A, Foloppe N, Hubbard RE, Aherne W, Pearl L, Jones K, McDonald E, Raynaud F, Eccles S, Drysdale M, Workman P. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Mol Cancer Ther 2007; 6:1198-211. [PMID: 17431102 DOI: 10.1158/1535-7163.mct-07-0149] [Citation(s) in RCA: 108] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Although the heat shock protein 90 (HSP90) inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) shows clinical promise, potential limitations encourage development of alternative chemotypes. We discovered the 3,4-diarylpyrazole resorcinol CCT018159 by high-throughput screening and used structure-based design to generate more potent pyrazole amide analogues, exemplified by VER-49009. Here, we describe the detailed biological properties of VER-49009 and the corresponding isoxazole VER-50589. X-ray crystallography showed a virtually identical HSP90 binding mode. However, the dissociation constant (K(d)) of VER-50589 was 4.5 +/- 2.2 nmol/L compared with 78.0 +/- 10.4 nmol/L for VER-49009, attributable to higher enthalpy for VER-50589 binding. A competitive binding assay gave a lower IC(50) of 21 +/- 4 nmol/L for VER-50589 compared with 47 +/- 9 nmol/L for VER-49009. Cellular uptake of VER-50589 was 4-fold greater than for VER-49009. Mean cellular antiproliferative GI(50) values for VER-50589 and VER-49009 for a human cancer cell line panel were 78 +/- 15 and 685 +/- 119 nmol/L, respectively, showing a 9-fold potency gain for the isoxazole. Unlike 17-AAG, but as with CCT018159, cellular potency of these analogues was independent of NAD(P)H:quinone oxidoreductase 1/DT-diaphorase and P-glycoprotein expression. Consistent with HSP90 inhibition, VER-50589 and VER-49009 caused induction of HSP72 and HSP27 alongside depletion of client proteins, including C-RAF, B-RAF, and survivin, and the protein arginine methyltransferase PRMT5. Both caused cell cycle arrest and apoptosis. Extent and duration of pharmacodynamic changes in an orthotopic human ovarian carcinoma model confirmed the superiority of VER-50589 over VER-49009. VER-50589 accumulated in HCT116 human colon cancer xenografts at levels above the cellular GI(50) for 24 h, resulting in 30% growth inhibition. The results indicate the therapeutic potential of the resorcinylic pyrazole/isoxazole amide analogues as HSP90 inhibitors.
Collapse
Affiliation(s)
- Swee Y Sharp
- Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Barril X, Beswick MC, Collier A, Drysdale MJ, Dymock BW, Fink A, Grant K, Howes R, Jordan AM, Massey A, Surgenor A, Wayne J, Workman P, Wright L. 4-Amino derivatives of the Hsp90 inhibitor CCT018159. Bioorg Med Chem Lett 2006; 16:2543-8. [PMID: 16480864 DOI: 10.1016/j.bmcl.2006.01.099] [Citation(s) in RCA: 71] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2006] [Revised: 01/18/2006] [Accepted: 01/18/2006] [Indexed: 11/29/2022]
Abstract
Novel piperazinyl, morpholino and piperidyl derivatives of the pyrazole-based Hsp90 inhibitor CCT018159 are described. Structure-activity relationships have been elucidated by X-ray co-crystal analysis of the new compounds bound to the N-terminal domain of human Hsp90. Key features of the binding mode are essentially identical to the recently reported potent analogue VER-49009. The most potent of the new compounds has a methylsulfonylbenzyl substituent appended to the piperazine nitrogen, possesses an IC50 of less than 600 nM binding against the enzyme and demonstrates low micromolar inhibition of tumour cell proliferation.
Collapse
|
9
|
Howes R, Barril X, Dymock BW, Grant K, Northfield CJ, Robertson AGS, Surgenor A, Wayne J, Wright L, James K, Matthews T, Cheung KM, McDonald E, Workman P, Drysdale MJ. A fluorescence polarization assay for inhibitors of Hsp90. Anal Biochem 2006; 350:202-13. [PMID: 16460658 DOI: 10.1016/j.ab.2005.12.023] [Citation(s) in RCA: 70] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2005] [Revised: 12/12/2005] [Accepted: 12/16/2005] [Indexed: 11/19/2022]
Abstract
Hsp90 encodes a ubiquitous molecular chaperone protein conserved among species which acts on multiple substrates, many of which are important cell-signaling proteins. Inhibition of Hsp90 function has been promoted as a mechanism to degrade client proteins involved in tumorigenesis and disease progression. Several assays to monitor inhibition of Hsp90 function currently exist but are limited in their use for a drug discovery campaign. Using data from the crystal structure of an initial hit compound, we have developed a fluorescence polarization assay to monitor binding of compounds to the ATP-binding site of Hsp90. This assay is very robust (Z' > 0.9) and can detect affinity of compounds with IC50s to 40 nM. We have used this assay in conjunction with cocrystal structures of small molecules to drive a structure-based design program aimed at the discovery and optimization of a novel class of potent Hsp90 inhibitors.
Collapse
Affiliation(s)
- R Howes
- Vernalis (Cambridge), Granta Park, Great Abington, Cambridge CB1 6GB, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Brough PA, Barril X, Beswick M, Dymock BW, Drysdale MJ, Wright L, Grant K, Massey A, Surgenor A, Workman P. 3-(5-Chloro-2,4-dihydroxyphenyl)-pyrazole-4-carboxamides as inhibitors of the Hsp90 molecular chaperone. Bioorg Med Chem Lett 2005; 15:5197-201. [PMID: 16213716 DOI: 10.1016/j.bmcl.2005.08.091] [Citation(s) in RCA: 63] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2005] [Revised: 08/09/2005] [Accepted: 08/22/2005] [Indexed: 11/21/2022]
Abstract
Information from X-ray crystal structures of Hsp90 inhibitors bound to the human Hsp90 molecular chaperone was used to assist in the design of 3-(5-chloro-2,4-dihydroxyphenyl)-pyrazole-4-carboxamides as novel inhibitors of Hsp90. Accessing an extra interaction with the protein via Phe138 gave a significant increase in binding potency compared to similar analogues that do not make this interaction.
Collapse
Affiliation(s)
- Paul A Brough
- Vernalis Ltd, Granta Park, Great Abington, Cambridge CB1 6GB, UK.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Barril X, Brough P, Drysdale M, Hubbard RE, Massey A, Surgenor A, Wright L. Structure-based discovery of a new class of Hsp90 inhibitors. Bioorg Med Chem Lett 2005; 15:5187-91. [PMID: 16202589 DOI: 10.1016/j.bmcl.2005.08.092] [Citation(s) in RCA: 65] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2005] [Revised: 08/11/2005] [Accepted: 08/22/2005] [Indexed: 12/01/2022]
Abstract
Docking-based virtual screening identified 1-(2-phenol)-2-naphthol compounds as a new class of Hsp90 inhibitors of low to sub-micromolar potency. Here we report the binding affinities and cellular activities of several members of this class. A high resolution crystal structure of the most potent compound reveals its binding mode in the ATP binding site of Hsp90, providing a rationale for the observed activity of the series and suggesting strategies for developing compounds with improved properties.
Collapse
Affiliation(s)
- Xavier Barril
- Vernalis (R&D) Ltd, Granta Park, Abington, Cambridge CB1 6GB, UK.
| | | | | | | | | | | | | |
Collapse
|
12
|
Dymock BW, Barril X, Brough PA, Cansfield JE, Massey A, McDonald E, Hubbard RE, Surgenor A, Roughley SD, Webb P, Workman P, Wright L, Drysdale MJ. Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J Med Chem 2005; 48:4212-5. [PMID: 15974572 DOI: 10.1021/jm050355z] [Citation(s) in RCA: 193] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The crystal structure of a previously reported screening hit 1 (CCT018159) bound to the N terminal domain of molecular chaperone Hsp90 has been used to design 5-amide analogues. These exhibit enhanced potency against the target in binding and functional assays with accompanying appropriate cellular pharmacodynamic changes. Compound 11 (VER-49009) compares favorably with the clinically evaluated 17-AAG.
Collapse
Affiliation(s)
- Brian W Dymock
- Vernalis Ltd., Granta Park, Great Abington, Cambridge, UK
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Wright L, Barril X, Dymock B, Sheridan L, Surgenor A, Beswick M, Drysdale M, Collier A, Massey A, Davies N, Fink A, Fromont C, Aherne W, Boxall K, Sharp S, Workman P, Hubbard RE. Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms. ACTA ACUST UNITED AC 2005; 11:775-85. [PMID: 15217611 DOI: 10.1016/j.chembiol.2004.03.033] [Citation(s) in RCA: 197] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2004] [Revised: 03/02/2004] [Accepted: 03/24/2004] [Indexed: 11/27/2022]
Abstract
Inhibition of the ATPase activity of the chaperone protein HSP90 is a potential strategy for treatment of cancers. We have determined structures of the HSP90alpha N-terminal domain complexed with the purine-based inhibitor, PU3, and analogs with enhanced potency both in enzyme and cell-based assays. The compounds induce upregulation of HSP70 and downregulation of the known HSP90 client proteins Raf-1, CDK4, and ErbB2, confirming that the molecules inhibit cell growth by a mechanism dependent on HSP90 inhibition. We have also determined the first structure of the N-terminal domain of HSP90beta, complexed with PU3. The structures allow a detailed rationale to be developed for the observed affinity of the PU3 class of compounds for HSP90 and also provide a structural framework for design of compounds with improved binding affinity and drug-like properties.
Collapse
Affiliation(s)
- Lisa Wright
- Vernalis (R&D) Ltd., Granta Park, Abington, Cambridge CB1 6GB, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Dymock B, Barril X, Beswick M, Collier A, Davies N, Drysdale M, Fink A, Fromont C, Hubbard RE, Massey A, Surgenor A, Wright L. Adenine derived inhibitors of the molecular chaperone HSP90—SAR explained through multiple X-ray structures. Bioorg Med Chem Lett 2004; 14:325-8. [PMID: 14698151 DOI: 10.1016/j.bmcl.2003.11.011] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Multiple co-crystal structures of an adenine-based series of inhibitors bound to the molecular chaperone Hsp90 have been determined. These structures explain the observed SAR for previously described compounds and new compounds, which possess up to 8-fold improved potency against the isolated enzyme. Anti-tumour cell potency and mechanism of action data is also described for the most potent compounds. These data should enable the design of more potent Hsp90 inhibitors.
Collapse
Affiliation(s)
- Brian Dymock
- RiboTargets Ltd, Granta Park, CB1 6GB, Cambridge, UK.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Hobbs CJ, Bit RA, Cansfield AD, Harris B, Hill CH, Hilyard KL, Kilford IR, Kitas E, Kroehn A, Lovell P, Pole D, Rugman P, Sherborne BS, Smith IED, Vesey DR, Walmsley DL, Whittaker D, Williams G, Wilson F, Banner D, Surgenor A, Borkakoti N. Structure-based design of peptidomimetic antagonists of p56(lck) SH2 domain. Bioorg Med Chem Lett 2002; 12:1365-9. [PMID: 11992778 DOI: 10.1016/s0960-894x(02)00167-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Starting from the tetrapeptide Ac-pYEEI-NHMe and using a structure-based approach, we have designed and synthesised a peptidomimetic ligand for p56(lck) SH2 domain containing a conformationally restricted replacement for the two glutamate residues. We have explored replacments for the isoleucine residue in the pY+3 pocket and thus identified 1-(R)-amino-3-(S)-indaneacetic acid as the most potent replacement. We also report the X-ray crystal structures of two of the antagonists.
Collapse
Affiliation(s)
- Christopher J Hobbs
- Roche Products Limited, 40 Broadwater Road, Welwyn Garden City, AL7 3AY, Hertfordshire, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|